AACP
KROS icon

Advantage Alpha Capital Partners’s Keros Therapeutics KROS Stock Holding History

Advantage Alpha Capital Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,059
Closed -$286K – 65
2025
Q3 		$286K Buy
+18,059
New +$267K 0.09% 118

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Advantage Alpha Capital Partners's KROS Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 18,059 shares — an estimated $286K sold.

Advantage Alpha Capital Partners first reported a position in KROS in Q3 2025 and held it in 1 quarter. The position peaked at $286K in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 18,059 Keros Therapeutics shares in Q4 2025, an estimated $286K.
  • Advantage Alpha Capital Partners first reported a position in Keros Therapeutics in Q3 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Keros Therapeutics position peaked at $286K in Q3 2025.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.